Literature DB >> 19286483

Decreased inflammation and augmented expression of trophic factors correlate with MOG-induced neuroprotection of the injured nigrostriatal system in the murine MPTP model of Parkinson's disease.

I Kurkowska-Jastrzebska1, E Bałkowiec-Iskra, A Ciesielska, I Joniec, A Cudna, M M Zaremba, A Członkowski, A Członkowska.   

Abstract

The response of the immune system during injury of the central nervous system may play a role in protecting neurons. We have previously reported that immunization with MOG 35-55 prior to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced injury of the dopaminergic system promotes less dopamine depletion and less dopaminergic damage of neurons in mice. In this study, we evaluate the influence of MOG immunization on the inflammatory reaction that occurs at the place of injury. C57Bl male mice, 2 and 12 months old, received i.p. injections of MPTP (40 mg/kg) and some groups animals also received an additional injection with myelin oligodendrocyte glycoprotein (MOG) 35-55 in CFA 6 days before MPTP administration. MPTP caused a common inflammatory reaction characterized by microglial activation, infiltration of T cells into the substantia nigra and striatum and increased expression of mRNA encoding pro-inflammatory cytokines (IL-1 beta, TNFalpha, INF gamma) and trophic factors (TGFbeta, GDNF). MOG immunization prior to MPTP administration significantly diminished the microglial reaction and reduced the levels of infiltrating CD8+ lymphocytes. The number of CD4+ T cells remained at the same level as in the MPTP group. Expression of pro-inflammatory cytokines was diminished. The mRNA expression of GDNF was significantly higher in the MOG pretreated mice relative to the MPTP group, both in the 2 month old and 12 month old groups. Since MOG immunization prior to MPTP intoxication appears to prevent nigrostriatal injury, the observed decrease of inflammation and increase of GDNF mRNA expression in the injured areas might represent one of the mechanisms of observed neuroprotection.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19286483     DOI: 10.1016/j.intimp.2009.03.003

Source DB:  PubMed          Journal:  Int Immunopharmacol        ISSN: 1567-5769            Impact factor:   4.932


  9 in total

Review 1.  MPTP mouse models of Parkinson's disease: an update.

Authors:  Gloria E Meredith; David J Rademacher
Journal:  J Parkinsons Dis       Date:  2011       Impact factor: 5.568

2.  Immune effects of optimized DNA vaccine and protective effects in a MPTP model of Parkinson's disease.

Authors:  Zhongmei Chen; Yunpeng Yang; Xu Yang; Changqing Zhou; Fengqun Li; Peng Lei; Ling Zhong; Xin Jin; Guoguang Peng
Journal:  Neurol Sci       Date:  2013-01-25       Impact factor: 3.307

3.  NADPH ameliorates MPTP-induced dopaminergic neurodegeneration through inhibiting p38MAPK activation.

Authors:  Jing-Si Zhou; Zhou Zhu; Feng Wu; Ying Zhou; Rui Sheng; Jun-Chao Wu; Zheng-Hong Qin
Journal:  Acta Pharmacol Sin       Date:  2018-05-16       Impact factor: 6.150

4.  17α-Ethynyl-androst-5-ene-3β,7β,17β-triol (HE3286) Is Neuroprotective and Reduces Motor Impairment and Neuroinflammation in a Murine MPTP Model of Parkinson's Disease.

Authors:  Ferdinando Nicoletti; Ingrid Philippens; Paolo Fagone; Clarence N Ahlem; Christopher L Reading; James M Frincke; Dominick L Auci
Journal:  Parkinsons Dis       Date:  2012-09-26

5.  IFN-γ signaling, with the synergistic contribution of TNF-α, mediates cell specific microglial and astroglial activation in experimental models of Parkinson's disease.

Authors:  C Barcia; C M Ros; V Annese; A Gómez; F Ros-Bernal; D Aguado-Yera; M E Martínez-Pagán; V de Pablos; E Fernandez-Villalba; M T Herrero
Journal:  Cell Death Dis       Date:  2011-04-07       Impact factor: 8.469

6.  The phosphodiesterase inhibitor, ibudilast, attenuates neuroinflammation in the MPTP model of Parkinson's disease.

Authors:  Joanna Schwenkgrub; Malgorzata Zaremba; Ilona Joniec-Maciejak; Agnieszka Cudna; Dagmara Mirowska-Guzel; Iwona Kurkowska-Jastrzębska
Journal:  PLoS One       Date:  2017-07-28       Impact factor: 3.240

7.  Disrupted myelination network in the cingulate cortex of Parkinson's disease.

Authors:  Song Xie; Jiajun Yang; Shenghui Huang; Yuanlan Fan; Tao Xu; Jiangshuang He; Jiahao Guo; Xiang Ji; Zhibo Wang; Peijun Li; Jiangfan Chen; Yi Zhang
Journal:  IET Syst Biol       Date:  2022-04-08       Impact factor: 1.468

Review 8.  Glial-mediated inflammation underlying parkinsonism.

Authors:  Carlos Barcia
Journal:  Scientifica (Cairo)       Date:  2013-07-11

Review 9.  Animal models of Parkinson's disease: a guide to selecting the optimal model for your research.

Authors:  Joana Lama; Yazead Buhidma; Edward J R Fletcher; Susan Duty
Journal:  Neuronal Signal       Date:  2021-12-08
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.